Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells
During the implementation of the project, it is planned to develop a method for the treatment of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells. The positive outlook for the effectiveness of MSCs is due to the following: * knowledge of the leading role of immunopathogenetic mechanisms in the development of acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs; * high tropism of MSCs to lung tissue when administered intravenously; * the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in the treatment of acute damage to the myocardium and kidneys, which will contribute to the treatment of multiple organ failure; * positive results of preclinical studies of the method of treatment of viral pneumonia in animals, and the first clinical studies in patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Standard treatment according to the Clinical protocols
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, Belarus
Number of cured patients
Number of patients cured, assessed by PCR in addition to chest CT scan
Time frame: 3 weeks
Number of patients with treatment-related adverse events
MSC infusion related adverse events assessed by blood count, liver and function tests
Time frame: 3 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.